K
Katharina Seystahl
Researcher at University of Zurich
Publications - 42
Citations - 757
Katharina Seystahl is an academic researcher from University of Zurich. The author has contributed to research in topics: Bevacizumab & Internal medicine. The author has an hindex of 11, co-authored 33 publications receiving 532 citations. Previous affiliations of Katharina Seystahl include University of Düsseldorf.
Papers
More filters
Journal ArticleDOI
Therapeutic options in recurrent glioblastoma--An update.
TL;DR: Proper patient selection, development of predictive biomarkers and randomized controlled studies are required to develop evidence-based concepts for recurrent glioblastoma.
Journal ArticleDOI
Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake
Katharina Seystahl,Veit M Stoecklein,Ulrich Schüller,Elisabeth J. Rushing,Guillaume Nicolas,Niklaus Schäfer,Harun Ilhan,Athina Pangalu,Michael Weller,Jörg-Christian Tonn,Michael Sommerauer,Nathalie L. Albert +11 more
TL;DR: In this paper, the safety and efficacy of SSTR-targeted radionuclide therapy (median of 3 treatment cycles, median administered dose/cycle 7400 MBq) led to a disease stabilization in 10 of 20 patients for a median time of 17 months.
Journal ArticleDOI
Differential regulation of TGF-β–induced, ALK-5–mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma
TL;DR: TGF-β regulates VEGF release by glioma cells in an ALK-5-dependent manner involving SMAD2, SMAD3, and SMAD1/5/8 signaling, which may open up new avenues of biomarker-driven exploratory clinical trials focusing on the microenvironment in glioblastoma.
Journal ArticleDOI
Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.
Emese Szabo,Hannah Schneider,Katharina Seystahl,Elisabeth J. Rushing,Frank Herting,K. Michael Weidner,Michael Weller +6 more
TL;DR: Differential dependence on autocrine signaling through V EGFR1 and VEGFR2 suggests a need for biomarker–stratified VEGF(R)-based therapeutic approaches to glioblastoma.
Journal ArticleDOI
Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma
Julia Furtner,Veronika Schöpf,Katharina Seystahl,Emilie Le Rhun,Emilie Le Rhun,Roberta Rudà,Ulrich Roelcke,Susanne Koeppen,Anna S. Berghoff,Christine Marosi,Paul Clement,Marina Faedi,Colin Watts,Wolfgang Wick,Riccardo Soffietti,Michael Weller,Matthias Preusser +16 more
TL;DR: The data indicate that systemic therapy may inhibit growth of recurrent WHO grades II and III meningiomas to some extent, and bevacizumab had the most pronounced inhibitory effect on tumor growth, as well as some anti-edematous activity.